Document:

First Amendment to Exclusive License Agreement, dated June 23, 2006

 Exhibit 10.4 
 FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 
 For Licensing Patent Rights 
 This First Amendment, made and entered into as of June 23, 2006(the First Amendment Effective
Date”) by and between THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate, having its principal office at 201 Regent Hall, Regent Drive, Boulder, CO 80309 (hereinafter “University”) and ARCA Discovery, Inc., a Delaware
corporation having its principal office at 1200 17th Street, Suite 620, Denver, CO 80202 (hereinafter “Licensee”), amends that
certain Exclusive Licensing Agreement between the Parties dated October 14, 2005 (the “License Agreement”). 
 WITNESSETH 
 WHEREAS, University owns certain Patent Rights (as defined in the License Agreement) relating to a
method of treating heart failure with bucindolol, identified as University Case nos. CU1297H and CU1298H, and set forth on Appendix A hereto (the “Bucindolol Patent Rights”), developed by inventors Michael Bristow et. al, and
previously licensed its interest in the Bucindolol Patent Rights to Licensee under the License Agreement; and 
 WHEREAS, the University of
Cincinnati (“Cincinnati”) is co-owner with University of the Bucindolol Patent Rights, identified as UC Technology Case 104-040; and 
 WHEREAS, Cincinnati has assigned its interest in the Bucindolol Patent Rights to University, pursuant to that certain Patent Assignment Agreement dated June 22, 2006 between Cincinnati and University (the
“Patent Assignment Agreement”); and 
 WHEREAS, Licensee is interested in obtaining exclusive rights to all of the
Bucindolol Patent Rights in order to develop them for commercial applications; and 
 WHEREAS, University desires to have the Bucindolol
Patent Rights developed and commercialized to benefit the public and is willing to amend the License Agreement in order to convey the interest formerly held by Cincinnati to Licensee, so that Licensee obtains an exclusive license of both
Cincinnati’s and University’s interest in the Bucindolol Patent Rights. 
 NOW, THEREFORE, in consideration of the premises and the
mutual covenants contained herein, the parties hereto agree as follows: 
 ARTICLE 1. DEFINITIONS 
 For the purposes of this Amendment, the following words and phrases shall have the following meanings: 
  

	1.01	“Cincinnati Patent Rights” mean Cincinnati’s ownership interest in the Bucindolol Patent Rights, which was conveyed to University in the Patent Assignment Agreement.

  

 1 of 3 

 All other definitions used herein shall have the same meaning as defined in the License Agreement. 
 ARTICLE 2. GRANT OF RIGHTS AND ACCEPTANCE 
  

	2.01	The License Agreement is hereby amended to add the Cincinnati Patent Rights to the Bucindolol Patent Rights previously licensed to Licensee under the License Agreement. The intent
of this Amendment is to grant Licensee an exclusive license to the entire Bucindolol Patent Rights, including the Cincinnati Patent Rights. 

  

	2.02	As consideration for this grant, Licensee shall issue to University 90,000 shares of ARCA Common Stock, pursuant to the Subscription Agreement between Licensee and University dated
June 23, 2006. No additional Royalties, milestone payments, or any other consideration shall be owed by Licensee under this Amendment. 

 ARTICLE 3. MISCELLANEOUS 
  

	11.01 	Except as expressly amended by this Amendment, all provisions of the License Agreement shall remain in full force and effect. 

  

	11.02 	This Amendment shall be governed by and construed in accordance with the laws of the State of Colorado. 

  

	11.03 	The provisions and clauses of this Amendment are severable, and in the event that any provision or clause is determined to be invalid or unenforceable under any controlling body of
the law, such invalidity or unenforceability will not in any way affect the validity or enforceability of the remaining provisions and clauses hereof. 

 IN WITNESS WHEREOF the parties hereto have caused this First Amendment, which is effective on the First Amendment Effective Date, to be executed in duplicate by their respective duly authorized officers. 

 

									
	University:	 		 	Licensee:
			
	The Regents of the University of Colorado	 		 	ARCA Discovery, Inc.
					
	By:	 	/s/ David N Allen	 		 	By:	 	/s/ Timothy D. Hoogheem
	Title:	 	Associate VP	 		 	Title:	 	Chief Business & Financial Officer
	Date:	 	June 23, 2006	 		 	Date:	 	June 23, 2006

  

 2 of 3 

 APPENDIX A 
 BUCINDOLOL PATENT RIGHTS 
  

					
	 UC104-040
 CU1297H
	  	[ * ]	  	[ * ]
			
	 UC104-040
 CU1298H
	  	[ * ]	  	[ * ]
			
	 UC104-040
 CU1297H/
 CU1298H
	  	[ * ]	  	[ * ]

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 3 of 3Second Amendment to Exclusive License Agreement, dated July 20, 2006

 Exhibit 10.5 
 SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 
 For Licensing Patent Rights 
 This Second Amendment is made and entered into as of July 20, 2006 (the “Second
Amendment Effective Date”) by and between THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate, having its principal office at 201 Regent Hall, Regent Drive, Boulder, CO 80309 (hereinafter “University”) and ARCA Discovery,
Inc., a Delaware corporation having its principal office at 1200 17th Street, Suite 620, Denver, CO 80202 (hereinafter “Licensee”).

 WITNESSETH 
 WHEREAS, the parties entered into an Exclusive License Agreement on October 14, 2005 (the “License Agreement”); and 
 WHEREAS, the License Agreement was subsequently amended on June 23, 2006; and 
 WHEREAS, pursuant to the terms
of the License Agreement, Licensee has an option to exclusively license the Inventions (as defined in the License Agreement); and 
 WHEREAS, University owns certain Patent Rights (as defined in the License Agreement) relating to two biologic pathways involving proteins known as “YY1 and Cardiac Hypertrophy” and “ERK1/2 and Cardiac
Hypertrophy”, and identified as University Case nos. CU1402H and CU1403H, as set forth on Appendix A hereto (collectively, the “YY1 and ERK1/2 Patent Rights” or the “Inventions”), developed by inventors Carmen
Sucharov et al; and 
 WHEREAS, Licensee desires to extend the time period for exercising this option while it investigates the
commercial potential of the Inventions; and 
 WHEREAS, University desires to have Licensee license the Inventions and is willing to
extend the option period in order to allow Licensee additional time to evaluate the Inventions. 
 NOW, THEREFORE, in consideration of
the premises and the mutual covenants contained herein, and for good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows: 
 ARTICLE 1. DEFINITIONS 
  

	1.01	Any defined terms not defined herein shall have the same meaning as defined in the License Agreement. 

  

 1 of 4 

 ARTICLE 2. EXTENSION OF OPTION 
  

	2.01	The License Agreement is hereby amended to grant Licensee an exclusive option to license the YY1 and ERK1/2 Patent Rights, on the terms provided for in the License Agreement (except
as otherwise modified herein), which option shall expire on the
 one-year anniversary of the date of this Second Amendment. 

  

	2.02	The license fee for each of the Inventions shall be [ * ], as provided in Section 2.03 (b)(2) of the License Agreement, with the following modification: In the event
that Licensee does not pay the license fee for one or both Inventions within 60 days of the execution of this Second Amendment, the license fee for the Inventions that remain unlicensed shall [ * ] for the remainder of the option period.

  

	2.03	Licensee shall be responsible for the preparation and filing, [ * ] of PCT patent applications (and additional U.S. utility applications if so preferred by Licensee) for
the YY1 and ERK1/2 Patent Rights. Licensee shall also be responsible for the diligent prosecution of such applications during the option period, or until the receipt of written notice from Licensee declining the Option, whichever is earlier,
[ * ]. Licensee shall keep University advised as to the status of the YY1 and ERK1/2 Patent Rights by providing University, in a timely manner prior to their due date, with copies of all official documents and material correspondence
relating to the prosecution, maintenance and validity of the YY1 and ERK1/2 Patent Rights. 

 ARTICLE 3. PERFORMANCE
MILESTONES 
  

	3.01	The following Performance Milestones shall, with respect to the Inventions only, be substituted for the Performance Milestones in Appendix E of the License Agreement, but shall:

 a. On or before January 1, 2008, Licensee shall deliver to University a business plan that communicates the
Licensee’s product development and marketing (strategic, tactical and financial) plans for the Inventions. This document shall include forecasts showing the funds, personnel and time budgeted and planned for development of any Licensed
Product(s) and Licensed
 Process(es) incorporating the Inventions. Licensee shall provide similar reports or updates, as the case may be, to University on [ * ]. 
 b. Licensee agrees that if any particular patent application or issued patent that is a part of the YY1 or ERK1/2 Patent Rights is not developed,
sublicensed, being diligently used in research and development, or being diligently pursued for commercialization, within two (2) years of the filing of the respective Patent Cooperation Treaty (PCT) or United States Utility Application,
Licensee shall relinquish all rights to that portion of the Patent Rights to University without additional compensation, credit or refund of any amounts paid. 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 2 of 4 

 ARTICLE 4. MISCELLANEOUS 
  

	4.01	Except as expressly amended by this Second Amendment, all provisions of the License Agreement shall remain in full force and effect. 

  

	4.02	This Second Amendment shall be governed by and construed in accordance with the laws of the State of Colorado. 

  

	4.03	The provisions and clauses of this Second Amendment are severable, and in the event that any provision or clause is determined to be invalid or unenforceable under any controlling
body of the law, such invalidity or unenforceability will not in any way affect the validity or enforceability of the remaining provisions and clauses hereof. 

 IN WITNESS WHEREOF the parties hereto have caused this Second Amendment, which is effective on the Second Amendment Effective Date, to be executed in
duplicate by their respective duly authorized officers. 
  

									
	University:	 		 	Licensee:
			
	The Regents of the University of Colorado	 		 	ARCA Discovery, Inc.
					
	By:	 	/s/ David N Allen	 		 	By:	 	/s/ Michael Bristow
	Title:	 	Associate VP	 		 	Title:	 	President and Chief Executive Officer
	Date:	 	August 9, 2006	 		 	Date:	 	August 11, 2006

  

			
	Approved as to Legal Sufficiency:
		
	By:	 	Illegible
	Title:	 	 
	Date:	 	 

  

 3 of 4 

 APPENDIX A 
 [ * ] 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 4 of 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]